Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$2.66
+2.1%
$3.05
$1.94
$12.32
$3.88M-0.04124,696 shs2,311 shs
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$0.00
$0.00
$0.16
$73K-0.0760,924 shsN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.65
+0.6%
$1.81
$1.32
$2.72
$239.50M1.71193,283 shs68,224 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.50
-0.8%
$5.77
$2.33
$110.75
$2.57M0.5753,845 shs72,589 shs
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
$0.52
$0.18
$20.46
$1.26M1.992.22 million shs52.49 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-1.14%+2.48%-22.53%+3.59%-59.04%
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00%0.00%0.00%0.00%+200.00%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%+7.89%-14.14%-7.34%-18.41%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
+0.80%-6.67%-41.53%-47.06%-97.18%
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
1.1908 of 5 stars
0.05.00.00.02.90.00.6
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.4544 of 5 stars
3.51.00.00.02.70.00.0
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
2.0367 of 5 stars
3.53.00.00.01.80.00.6
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00
N/AN/AN/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00
N/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00324.24% Upside
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
3.00
Buy$60.002,300.00% Upside
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EVOK, IMMP, ONCS, GNBT, and JAGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
First Berlin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$10.25M0.39N/AN/A$4.74 per share0.56
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$2.66M0.00N/AN/AN/ANaN
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M46.88N/AN/A$1.05 per share1.57
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.69M0.22N/AN/A$12.29 per share0.20
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
N/AN/AN/AN/A$3.42 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$5.35M-$2.87N/AN/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
-$33.33MN/A0.00N/AN/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/A

Latest EVOK, IMMP, ONCS, GNBT, and JAGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million
5/12/2025Q1 2025
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
1.55
1.50
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
22.20
1.08
0.70
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
N/A
0.89
0.89

Institutional Ownership

CompanyInstitutional Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
8.69%

Insider Ownership

CompanyInsider Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
6.10%
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
35.20%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.38%
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
1.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
41.49 million1.40 millionNot Optionable
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
15122.06 million79.09 millionNot Optionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
501.02 million1.01 millionNo Data
OncoSec Medical Incorporated stock logo
ONCS
OncoSec Medical
404.55 million4.49 millionNot Optionable

Recent News About These Companies

PVCT Provectus Biopharmaceuticals, Inc.
ONCS - OncoSec Medical Incorporated
0 analysts rank ONCS stock as an Overweight
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evoke Pharma stock logo

Evoke Pharma NASDAQ:EVOK

$2.64 +0.04 (+1.38%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Generex Biotechnology stock logo

Generex Biotechnology OTCMKTS:GNBT

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.65 +0.01 (+0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.61 -0.04 (-2.67%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$2.50 -0.02 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$2.51 +0.01 (+0.40%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

OncoSec Medical stock logo

OncoSec Medical NASDAQ:ONCS

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.